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Abstract
Introduction:  Chemoradiotherapy  for  squamous  cell  carcinoma  of  the  oropharynx  (SCCO)  pro-
vides good  results  for  locoregional  disease  control,  with  high  rates  of  complete  clinical  and
pathologic responses,  mainly  in  the  neck.
Objective:  To  determine  whether  complete  pathologic  response  after  chemoradiotherapy  is
related to  the  prognosis  of  patients  with  SCCO.
Methods:  Data  were  prospectively  extracted  from  clinical  records  of  N2  and  N3  SCCO  patients
submitted  to  a  planned  neck  dissection  after  chemoradiotherapy.
Results:  A  total  of  19  patients  were  evaluated.  Half  of  patients  obtained  complete  pathologic
response  in  the  neck.  Distant  or  locoregional  recurrence  occurred  in  approximately  42%  of
patients,  and  26%  died.  Statistical  analysis  showed  an  association  between  complete  pathologic
response and  lower  disease  recurrence  rate  (77.8%  vs.  20.8%;  p  =  0.017)  and  greater  overall
survival (88.9%  vs.  23.3%;  p  =  0.049).
Conclusion:  The  presence  of  a  complete  pathologic  response  after  chemoradiotherapy  posi-
tively inﬂuences  the  prognosis  of  patients  with  SCCO.
© 2015  Associac¸ão  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Cérvico-Facial.  Published  by
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Resposta  patológica  completa  como  fator  prognóstico  no  carcinoma  espinocelular  de
orofaringe  após  quimiorradioterapia
Resumo
Introduc¸ão:  O  tratamento  baseado  em  quimirradioterapia  do  Carcinoma  Espinocelular  de  Oro-
faringe (CECOF)  apresenta  bons  resultados  no  controle  locorregional  da  doenc¸a  com  boas  taxas
de resposta  clínica  e  patológica  completas  especialmente  no  pescoc¸o.
Objetivo:  Determinar  se  a  resposta  patológica  completa  após  quimiorradioterapia  estárela-
cionada aos  prognósticos  dos  pacientes  com  CECOF.
Método:  Os  dados  foram  obtidos  de  maneira  prospectiva  da  revisão  de  prontuários  de  pacientes
com CECOF  N2  e  N3  submetidos  a  esvaziamento  cervical  planejado  após  quimiorradioterapia.
Resultados:  Um  total  de  19  pacientes  foram  avaliados.  Metade  dos  indivíduos  apresentou
resposta  patológica  completa  no  pescoc¸o.  Recidiva  à  distância  ou  locorregional  ocorreu  em
aproximadamente  42%  dos  pacientes  e  26%  deles  morreram.  A  análise  estatística  demonstrou
uma associac¸ão  entre  resposta  patológica  completa  e  menor  taxa  de  recidiva  (77,8%  vs.  20,8%;
p =  0,017)  e  maior  sobrevivência  global  (88,9%  vs.  23,3%;  p  =  0,049).
Conclusão:  A  presenc¸a  de  resposta  patológica  completa  após  quimiorradioterapia  inﬂuencia
positivamente  no  prognóstico  de  pacientes  com  carcinoma  espinocelular  de  orofaringe.
© 2015  Associac¸ão  Brasileira  de  Otorrinolaringologia  e  Cirurgia  Cérvico-Facial.  Publicado  por
Elsevier Editora  Ltda.  Todos  os  direitos  reservados.
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An  option  in  the  treatment  of  locally  advanced  squamous
cell  carcinoma  of  the  oropharynx  (SCCO)  is  chemother-
apy  and  radiotherapy  combined  with  organ  preservation,
also  targeting  local  and  regional  control  of  the  disease.1--6
This  therapeutic  approach  was  originally  devised  to  be  fol-
lowed  by  a  planned  neck  dissection  in  all  patients.7--9 Some
authors  suggest,  however,  that  this  approach  should  be
restricted  to  patients  with  N2  and  N3  stage  at  diagnosis,
or  to  those  patients  with  N1  stage  with  partial  response
after  treatment.10--12 However,  other  authors  argue  that  a
planned  neck  dissection  must  be  carried  out,  regardless  of
the  initial  stage,  considering  that  the  pathological  positiv-
ity  rate  after  treatment  reaches  30--40%.10,13 It  is  also  well
established  that  patients  with  residual  cervical  disease  after
chemoradiotherapy  have  an  increased  risk  of  locoregional
recurrence,  as  well  as  of  distant  disease.14--17
Thus,  the  aim  of  this  study  was  to  evaluate  whether  the
complete  pathologic  response  after  a  combined  treatment
with  chemoradiotherapy  is  associated  with  the  prognosis  in
patients  with  locally  advanced  squamous  cell  carcinoma  of
the  oropharynx.
Methods
This  was  a  prospective  cohort  study  approved  by  the  Institu-
tional  Ethics  Committee  under  protocol  No.  098/2008.  This
study  included  all  patients  with  IVa  or  IVb  stage  SCCO  (T1-
4a,  N2-3)  consecutively  submitted  to  chemoradiotherapy,
followed  by  planned  radical  neck  dissection  8--12  weeks
after  the  end  of  the  treatment,  in  the  period  from  Jan-
uary  2008  to  December  2010,  and  with  complete  response
at  the  primary  site  conﬁrmed  by  physical  examination,  pan-
endoscopy,  computed  tomography  (CT)  scan,  and  biopsy,
t
bhen  needed.  Complete  clinical  response  was  considered
hen  there  was  no  evidence  of  persistent  disease  in  these
xaminations;  complete  pathologic  response  was  consid-
red  when  the  specimen  obtained  through  the  planned  neck
issection  showed  no  pathological  evidence  of  active  malig-
ancy  (residual  tumor).  Response  assessment  was  deﬁned
ogether  in  a multidisciplinary  clinical  meeting,  including
ead  and  Neck  Surgery,  Oncology,  Radiology,  and  Pathology
ervices.  Platinum-based  chemotherapy  was  administered,
ith  a  minimal  radiotherapy  dose  of  5000  cGy  applied  to  the
ervical  bed.  In  this  scenario,  19  patients  were  included,
ith  a  minimum  of  two  years  of  follow-up  guaranteed  for
ll  participants.
Demographic,  clinical,  and  pathological  data  were
btained  from  medical  records.  The  pTNM  stage  was  revised
ased  on  the  seventh  edition  (2010)  of  the  Union  Interna-
ionale  Contre  le  Cancer  (UICC)  publication.  All  patients
ere  followed  monthly,  bimonthly,  and  every  three,  four,
nd  six  months,  respectively  for  the  ﬁrst,  second,  third,
ourth,  and  ﬁfth  post-treatment  year.  Human  papillomavirus
HPV)  status  was  assessed  retrospectively  at  the  time  of
ompletion  of  this  study  through  reviewing  the  parafﬁn
locks  for  the  presence  of  p16  protein;  the  specimen  was
onsidered  positive  when  immunoexpression  rates  were
bove  80%.  No  other  HPV  detection  methodology  was  per-
ormed,  because  of  unavailability  at  this  center.
The  primary  outcome  studied  was  progression-free  sur-
ival,  deﬁned  as  the  time  from  diagnosis  to  disease
ecurrence  (locoregional  or  distant).  Secondarily,  overall
urvival  was  studied,  measured  as  the  time  from  diagnosis
o  death  from  any  cause.  Patients  alive  without  evidence  of
isease  at  the  time  of  this  analysis  were  censored  at  the  last
ollow-up.For  statistical  analysis,  the  chi-squared  or  Fisher’s  exact
est  was  used  for  comparison  between  two  qualitative  varia-
les.  Kaplan--Meier  method  and  log-rank  test  were  used
500  
Table  1  Descriptive  data  of  patients  included  in  this  study.
Variable  Result
Gender
Male  15  (78.9%)
Female  4  (21.1%)
Age (years)a 55.8  ±  8.1
Primary  site
Soft  palate  1  (5.3%)
Tongue base  5  (26.3%)
Vallecula  3  (15.8%)
Palatine  tonsil 8  (42.1%)
Lateral  wall 2  (10.5%)
Habits
Smoking  17  (89.5%)
Alcoholism  15  (78.9%)
HPV-positive  status  (p16-positive)  1  (5.3%)
Pretreatment
Concomitant  chemoradiotherapy  12  (63.2%)
Induction  chemotherapy  followed
by  concomitant  chemoradiotherapy
7  (36.8%)
Initial clinical  stage
T  stage
T2  4  (21.1%)
T3 8  (42.1%)
T4 7  (36.8%)
N stage
N2a  7  (36.8%)
N2b 3  (15.8%)
N2c 2  (10.6%)
N3 7  (36.8%)
Complete  clinical  response  12  (63.2%)
Complete  pathological  response  10  (52.6%)
Progression
Locoregional  4  (21.1%)
Distant  4  (21.1%)
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pHPV, human papillomavirus.
a Mean ± standard deviation.
or  survival  analysis  and  for  comparing  curves,  respectively.
PSS  version  17.0  (SPSS  Inc--Illinois,  United  States)  was  used
or  all  analyzes,  and  the  level  of  statistical  signiﬁcance  was
et  at  5%  (p  ≤  0.05).
esults
ineteen  patients,  totaling  21  neck  dissections,  were
ncluded  (Table  1)  with  a  median  of  28  months  of  follow-
p.  Most  patients  were  male  (78.9%)  in  the  ﬁfth  decade  of
ife  (44--76  years),  and  were  smokers  and  drinkers.  Only  one
ositive  p16  case  was  detected.  Complete  clinical  response
as  observed  in  12  patients  (63.2%)  and  complete  patholog-
cal  response  in  ten  (52.6%).  Eight  cases  (42.2%)  had  disease
rogression  and  ﬁve  (26.3%)  suffered  disease-related  death.
In  the  univariate  analysis,  none  of  the  demographic,  clini-
al,  or  pathological  variables  were  associated  with  complete
athological  response,  as  shown  in  Table  2.
t
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Survival  analysis  showed  that  patients  with  complete
athological  response  had  higher  progression-free  survival
77.8%  vs.  20.8%;  p  =  0.017  --  log-rank  test)  and  overall  sur-
ival  (88.9%  vs.  23.3%;  p  =  0.049  --  log-rank  test)  rates,  as
etailed  in  Fig.  1.  The  medians  for  progression-free  survival
nd  overall  survival  for  patients  with  residual  cervical  dis-
ase  were  23.1  and  28.8  months,  respectively,  while  patients
ith  complete  pathologic  response  did  not  achieved  these
edians  over  the  60-month  follow-up.  Bearing  in  mind  that
his  was  a  retrospective  study,  in  the  analysis  of  these
ndings  the  power  of  this  estimate  was  calculated  using
he  method  of  comparison  between  two  proportions.  Faced
ith  the  obvious  differences  between  Kaplan--Meier  curves
88.9%  vs.  23.3%  for  progression-free  survival  and  77.8%  vs.
0.8%  for  overall  survival,  respectively  for  patients  with  vs.
ithout  complete  pathologic  response),  the  inclusion  of  19
atients  in  this  study  resulted  in  an  analytical  power  for  this
stimate  in  excess  of  95%.  For  a  conventional  analysis  (80%
est  power  and  5%  statistical  signiﬁcance),  it  was  estimated
hat  a  sample  between  eight  and  12  patients  would  suf-
ce  to  demonstrate  these  ﬁndings,  mainly  due  to  the  great
ifference  between  the  curves.
It  is  also  important  to  note  that  the  stratiﬁcation  of  the
esults  for  both  analyzes  (progression-free  and  overall  sur-
ivals)  for  potential  confounding  variables  (T  and  N  clinical
tages  and  previous  treatment  modalities)  did  not  alter  the
esults,  which  means  that  complete  pathological  response
as  a  better  prognostic  factor  in  patients  with  SCCO,  regard-
ess  of  other  variables.
iscussion
his  study  identiﬁed  that  52.6%  of  patients  in  IVa  and  IVb
tage  for  squamous  cell  carcinoma  of  the  oropharynx  show
omplete  pathological  response  after  chemoradiotherapy,
 ﬁnding  similar  to  other  studies.  Dhiwakar  et  al.18 stud-
ed  selective  neck  dissection  in  patients  with  squamous
ell  carcinoma  (SCC)  of  several  sites  in  the  head  and  neck
ith  partial  response  after  chemoradiotherapy,  including  39
ases  (63%)  of  SCCO.  These  authors  found  cervical  persis-
ence  in  32  neck  dissection  specimens  (46%);  22  patients
35%)  developed  recurrent  disease  (seven  at  the  primary
ite,  11  distant,  and  four  cases  in  the  neck,  but  only  one
psilateral  case).
A  study  carried  out  at  the  Sloan-Kettering  Memorial  Can-
er  Center19 that  evaluated  planned  neck  dissection  in  56
ost-chemoradiotherapy  patients  with  head  and  neck  SCC
71%  in  the  oropharynx)  found  that  presence  of  a  viable
umor  in  the  cervical  specimen  was  a  predictor  of  lower
verall  (49%)  and  disease-free  (56%)  survival,  as  well  as
f  lower  recurrence-free  (40%)  survival,  when  compared
o  patients  with  complete  cervical  pathological  response
93%,  93%,  and  75%,  respectively).  The  authors  also  reported
hat  63%  of  19  patients  with  a  viable  tumor  relapsed  during
ollow-up;  among  these,  eight  cases  also  developed  remote
isease.  Lango  et  al.20 found  similar  results,  with  37%  of
rogression-free  survival  in  patients  with  a  viable  tumor  in
he  cervical  specimen  vs.  85%  in  patients  with  complete
athological  response,  corroborating  the  prognostic  signiﬁ-
ance  of  residual  disease  after  chemoradiotherapy  in  these
atients.
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Table  2  Univariate  analysis:  variables  associated  with  complete  pathological  response.
Variable  Complete  pathological  response
No  Yes  p-value
Age  (years:  mean  ±  standard  deviation)  55.3  ±  9.0  56.4  ±  7.4  0.780a
Gender  0.303b
Male  6  (66.7%)  9  (90.0%)
Female 3  (33.3%)  1  (10.0%)
Primary site  0.543c
Soft  palate 1  (11.1%) 0  (0.0%)
Tongue base 1  (11.1%) 4  (40.0%)
Vallecula 2 (22.2%) 1  (10.0%)
Palatine tonsil  4  (44.4%)  4  (40.0%)
Lateral wall  1  (11.1%)  1  (10.0%)
Previous  treatment  1.000b
Concomitant  chemoradiotherapy  6  (66.7%)  6  (60.0%)
Induction  chemotherapy  followed  by  concomitant
chemoradiotherapy
3  (33.3%)  4  (40.0%)
Cervical irradiation  dose 0.370b
5000  cGy  6  (66.7%)  4  (40.0%)
7000 cGy  3  (33.3%)  6  (60.0%)
Primary neoplasia  differentiation  0.289c
Well  differentiated  1  (11.1%)  0  (0.0%)
Moderately  differentiated  7  (77.8%)  10  (100.0%)
Poorly differentiated  1  (11.1%)  0  (0.0%)
Initial clinical  stage
T  stage  0.326c
T2  3  (33.3%)  1  (10.0%)
T3 4  (44.4%)  4  (40.0%)
T4 2  (22.2%)  5  (50.0%)
N stage  0.462c
N2a  3  (33.3%)  4  (40.0%)
N2b 1  (11.1%)  2  (20.0%)
N2c 2  (22.2%)  0  (0.0%)
N3 3  (33.3%)  4  (40.0%)
Complete  clinical  response  0.650b
No  4  (44.4%)  3  (30.0%)
Yes 5  (55.6%)  7  (70.0%)
a Mann--Whitney test.
b
t
w
a
i
w
b
i
c
w
uFisher’s exact test.
c Chi-squared test.
The  present  study  also  found  that  the  presence  of  resid-
ual  tumor  in  the  cervical  specimen  obtained  from  planned
neck  dissection  in  SCCO  patients  treated  with  chemora-
diotherapy  was  associated  with  lower  overall  survival  and
disease-free  rates,  regardless  of  other  possible  confounding
variables--again  a  ﬁnding  which  is  similar  to  those  observed
by  other  authors.2,10,11,21 It  should  also  be  noted  that  the
present  study  included  19  consecutive  patients,  which  may
at  ﬁrst  be  considered  a  limited  sample;  however,  the  power
calculated  for  the  main  conducted  estimates  (differences  in
progression-free  and  overall  survivals)  exceeded  95%,  show-
ing  statistical  signiﬁcance  for  these  ﬁndings.
Krstevska  et  al.22 studied  chemoradiotherapy  as  primary
treatment  in  patients  with  III-  and  IV-stage  SCCO  and  found
d
c
s
shat  recurrence-free,  disease-free,  and  overall  survivals
ere  41.7%,  33.2%,  and  49.7%,  respectively.  Clayman  et  al.23
lso  studied  the  inﬂuence  of  complete  pathological  response
n  the  prognosis  for  patients  with  SCCO.  Sixty-six  patients
ith  N2a  stage  or  superior  were  submitted  to  platinum-
ased  induction  chemotherapy,  followed  by  radiotherapy
n  isolation.  Of  these  patients,  36%  achieved  complete
linical  and  radiological  responses.  Eighteen  patients  (17
ith  partial  response  and  one  case  of  complete  response)
nderwent  salvage  neck  dissection  and  12  (56%)  had  evi-
ence  of  residual  disease.  It  is  noteworthy  that  the  only
ase  of  complete  clinical  response  submitted  to  salvage
urgery  demonstrated  microscopic  disease  in  the  neck  dis-
ection  specimen.  Low  locoregional  recurrence  rate  was  also
502  Trufelli  DC  et  al.
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sigure  1  Overall  survival  (A)  and  progression-free  (B)  curve
og-rank test  for  overall  survival  and  77.8%  vs.  20.8%,  p  =  0.017  
dentiﬁed  in  patients  with  complete  clinical  response  for
heir  primary  tumor  after  treatment.  All  patients  requiring
alvage  neck  dissection  as  well  as  resection  of  the  primary
umor  because  of  disease  persistence  suffered  locoregional
ecurrence  during  follow-up--an  enormous  result  when  com-
ared  to  patients  not  submitted  to  any  rescue  procedure
12%)  or  to  those  treated  only  with  neck  dissection  (7%).  In
he  same  study,  disease-free  and  overall  survival  rates  were
9.2%  and  78.4%,  respectively,  for  the  entire  cohort.  A  sig-
iﬁcant  increase  was  observed  in  overall  survival  speciﬁcally
or  patients  undergoing  salvage  neck  dissection  (vs.  those
ithout  nodal  dissection)  who  achieved  complete  response
n  the  primary  site,  but  with  partial  response  in  the  neck
fter  chemoradiotherapy.  The  authors  also  recommend  that
atients  with  complete  clinical  or  radiological  response,  and
ven  those  who  had  a  bulky  cervical  disease,  should  only  be
onitored,  without  planned  neck  dissection,  because  none
f  the  29  patients  with  negative  results  by  CT  and  magnetic
esonance  imaging  suffered  neck  recurrence.
Returning  to  this  subject,  the  literature  suggests  that,
f  there  is  clinical  and  radiological  evidence  of  a  com-
lete  locoregional  response  after  chemoradiotherapy,  the
hance  of  residual  cervical  disease  will  be  less  than  20%.21
or  these  patients,  positron  emission  tomography  with  ﬂu-
rodeoxyglucose  (18-FDG  PET-CT)  is  the  primary  ancillary
est  to  be  used  in  a  cervical  assessment.  Some  studies  advo-
ate,  as  a  principle,  the  use  of  dissection  in  these  patients;
ut  the  most  recent  studies  do  not  recommend  neck  dissec-
ion  in  N2-  and  N3-stage  patients  with  evidence  of  clinical
r  imaging  response  (CT  and/or  18-FDG  PET-CT),  considering
he  low  residual  disease  rate  and  that  a  planned  procedure
ould  not  lead  to  improvement  in  overall  and  disease-
ree  survival  rates.  Thus,  it  is  recommended  that  neck
issection  is  performed  only  as  a  rescue  procedure.8,23--31
espite  the  literature  evaluated,  this  study  established  that
linical  response  (assessed  by  physical  examination,  pan-
ndoscopy,  and  computed  tomography)  was  not  associated
ith  complete  pathologic  response;  therefore,  a  planned
eck  dissection  could  still  be  an  indication  in  this  patient
roup.As  demonstrated,  some  institutions  and  protocols  argue
hat  a  18-FDG  PET-CT  negative  result  for  the  neck  is  suf-
cient  for  an  expectant  management  strategy.  In  theory,
his  would  obviate  the  need  for  a  planned  neck  dissection.
d
t
w
otiﬁed  for  pathological  response  (88.9%  vs.  23.3%;  p  =  0.049  --
-rank  test  for  survival  free  of  disease  progression).
owever,  a  recently  published  study32 reviewed  243  cases
f  patients  with  squamous  cell  carcinoma  of  head  and  neck
70%  of  the  oropharynx)  submitted  to  PET-CT  prior  to  their
lanned  neck  dissection  (112  N0-clinical  stage  patients  and
31  patients  with  a  clinically  positive  neck).  The  authors
ound  that  the  sensitivity,  speciﬁcity,  positive  predictive
alue,  negative  predictive  value,  and  accuracy  rates  were,
espectively,  57%,  82%,  59%,  80%,  and  74%  for  N0-clinical
tage  patients;  and  93%,  70%,  96%,  58%,  and  91%  for  patients
ith  evidence  of  lymph  node  disease.  Thus,  these  authors
oncluded  that  PET/CT  has  low  efﬁcacy  in  detecting  cervi-
al  metastases  of  N0-clinical  stage  patients,  compared  to
ndividuals  with  a  positive  neck;  and  that  the  method  is  not
eneﬁcial  for  staging  of  N0-clinical  stage  patients,  due  to
he  high  rates  of  false-positive  and  false-negative  results.
nother  important  point  to  be  considered  is  the  inaccessi-
ility  of  this  diagnostic  modality  in  many  oncology  centers.
his  further  underscores  the  importance  of  this  study  in
etermining  the  plan  of  treatment  for  this  population.  An
xpectant  strategy  can  still  be  adopted  in  patients  with  com-
lete  clinical  response  after  treatment,  with  good  long-term
isease-free  survival  rates.27
The  diversity  of  treatment  strategies  found  for  these
atients  denotes  the  complexity  of  this  subject.  In  addition,
avidnia  and  Corsten33 calculated  the  ‘‘number  needed  to
reat’’  (NNT)  in  patients  with  advanced  head  and  neck  SCC
N2  and  N3  stages)  based  on  a  systematic  review  of  15  stud-
es  with  a  total  of  817  patients.  The  calculated  NNT  value
as  7.5;  i.e.,  to  prevent  one  case  of  death  from  cervical
ecurrence  after  chemoradiotherapy,  7.5  cases  of  planned
eck  dissection  should  be  performed,  demonstrating  the
ost-effectiveness  of  the  procedure.
Goguen  et  al.34 studied  105  neck  dissection  specimens
fter  chemoradiotherapy,  including  83  cases  of  SCCO  (79%),
nd  found  that  the  presence  of  positive  lymph  nodes  was
igniﬁcantly  associated  with  a  decrease  in  the  progression-
ree  survival,  as  well  as  in  overall  survival.
Cupino  et  al.35 speciﬁcally  studied  patients  with  stage  IV
CCO  submitted  to  selective  (or  even  super-selective)  dis-
ection  after  chemoradiotherapy.  The  authors  found  rates  of
isease  control  of  95%  and  88%,  respectively,  after  two  and
hree  years  of  follow-up.  No  patient  had  cervical  recurrence,
ith  91%  remote  disease-free  survival  after  two  years,  and
verall  survival  of  88%  and  75%  in  two  and  three  years  of
amo
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follow-up,  respectively.  Despite  these  signiﬁcant  oncological
responses,  the  study  is  somewhat  debatable,  due  to  the  het-
erogeneity  of  dissected  cervical  levels  and  the  low  number
of  cases.  Esteller  et  al.36 included  a  diversiﬁed  group  of  head
and  neck  SCC,  with  34.2%  adjusted  ﬁve-year  overall  survival
rate  after  rescue  surgery.  In  an  earlier  study,24 the  same
group  found  that  N3-stage  patients  were  at  increased  risk  of
cervical  residual  disease  after  chemoradiotherapy;  and  that
N2-stage  patients  with  complete  response  after  treatment
(evaluated  by  physical  examination,  neck  CT,  and  PET-CT)
did  not  require  planned  neck  dissection,  because  such  a  pro-
cedure  does  not  increase  overall  survival  and  disease-free
rates.
Conclusion
The  complete  pathologic  response  after  chemoradiotherapy
positively  inﬂuences  the  prognosis  of  patients  with  squa-
mous  cell  carcinoma  of  the  oropharynx,  with  better  rates
of  survival  free  of  disease  progression,  as  well  as  of  overall
survival  --  results  similar  to  those  found  in  the  literature.
However,  more  studies,  especially  with  larger  series,  should
be  performed  to  establish  a  therapeutic  guideline  based  on
more  consistent  scientiﬁc  evidence.
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